September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
|Articles|December 31, 2006
The ABC’s of Distracting a Child From Suture Pain
To reduce the pain of a corticosteroid/lidocaine injectioninto the heel, first mark the location with ink and then applyan ice pack for 5 to 10 minutes.
Advertisement
To reduce the pain of a corticosteroid/lidocaine injectioninto the heel, first mark the location with ink and then applyan ice pack for 5 to 10 minutes. The injection can usuallythen be given with little or no reaction from the patient.-- Craig Freyer, MD
Fort Worth, Tex
Advertisement
Related to this article
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Advertisement
Advertisement
Trending on Patient Care Online
1
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
5